Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
36 hedge funds and large institutions have $7.53M invested in Regulus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 14 closing their positions.
13.43% less ownership
Funds ownership: 49.77% → 36.34% (-13%)
22% less funds holding
Funds holding: 46 → 36 (-10)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
94% less capital inflows, than outflows
Capital inflows: $257K | Capital outflows: $4.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$131K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$80.4K |
| 3 |
Wedbush Securities
Los Angeles,
California
|
+$20.2K |
| 4 |
Panagora Asset Management
Boston,
Massachusetts
|
+$11.7K |
| 5 |
Two Sigma Securities
New York
|
+$4.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$486K |
| 3 |
South Dakota Investment Council
Sioux Falls,
South Dakota
|
-$361K |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$330K |
| 5 |
DRW Securities
Chicago,
Illinois
|
-$89K |
RGLS Hedge Fund Activity: Q3 2018 in Review
36 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2018, worth a combined $7.53M — down 78% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RGLS and 4 opened new positions — a net loss of 10 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $131K. The largest seller was Fidelity Investments, cutting an estimated $3.21M.
- 36 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2018, down from 46 in Q2 2018.
- Funds reported $7.53M of Regulus Therapeutics stock for Q3 2018, down 78% quarter-over-quarter.
- 4 funds opened new Regulus Therapeutics positions in Q3 2018 and 14 closed out, a net change of -10 holders.
- The largest Regulus Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $131K added.
- The largest Regulus Therapeutics seller in Q3 2018 was Fidelity Investments, an estimated $3.21M sold.
Based on aggregated 13F filings for Q3 2018.